Metsera (NASDAQ:MTSR) Lowered to Hold Rating by Leerink Partnrs

Key Points

• Metsera (NASDAQ:MTSR) was downgraded from a "strong-buy" to a "hold" rating by Leerink Partners, highlighting a shift in analyst sentiment toward the stock.
• Despite the downgrade, five analysts still maintain a Buy rating on Metsera, with an average target price of $58.50.
• The company's recent stock performance shows a 0.9% decline, with shares opening at $52.50 and a notable 52-week price range of $12.30 to $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) was downgraded by Leerink Partnrs from a "strong-buy" rating to a "hold" rating in a note issued to investors on Wednesday,Zacks.com reports.

MTSR has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a report on Wednesday, September 3rd. Guggenheim upped their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Bank of America raised their target price on Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Wells Fargo & Company started coverage on Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 target price on the stock. Finally, Wall Street Zen cut Metsera from a "hold" rating to a "sell" rating in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $58.50.

Metsera Stock Down 0.9%

Shares of NASDAQ MTSR opened at $52.50 on Wednesday. The firm's 50-day moving average price is $36.09 and its 200-day moving average price is $29.68. Metsera has a 52-week low of $12.30 and a 52-week high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Hedge Funds Weigh In On Metsera

A number of hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. raised its stake in Metsera by 45.5% during the 2nd quarter. Osaic Holdings Inc. now owns 946 shares of the company's stock valued at $27,000 after purchasing an additional 296 shares during the period. Corient Private Wealth LLC purchased a new stake in Metsera during the 2nd quarter valued at approximately $373,000. Rafferty Asset Management LLC purchased a new position in shares of Metsera in the second quarter worth $549,000. Eventide Asset Management LLC lifted its holdings in shares of Metsera by 58.5% in the second quarter. Eventide Asset Management LLC now owns 396,160 shares of the company's stock worth $11,271,000 after buying an additional 146,160 shares in the last quarter. Finally, EcoR1 Capital LLC boosted its position in shares of Metsera by 443.1% during the second quarter. EcoR1 Capital LLC now owns 271,529 shares of the company's stock worth $7,725,000 after acquiring an additional 221,529 shares during the last quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.